What is Pepticom?
Pepticom specializes in designing innovative peptide drug candidates by leveraging biocomputational AI software. Their proprietary platform aims to optimize the drug discovery process, thereby accelerating time to market and mitigating development risks and costs. The company's mission is to enhance access to advanced peptide therapeutics by focusing on AI-driven discovery of effective binding peptides for target interactions and offering a robust platform for designing superior drug candidates across various chemical structures. Pepticom engages in both collaborative and in-house development projects during the discovery phase to foster drug innovation.
How much funding has Pepticom raised?
Pepticom has raised a total of $14.2M across 3 funding rounds:
Series A
$5M
Other Financing Round
$2.6M
Series A
$6.6M
Series A (2019): $5M with participation from Chartered Group
Other Financing Round (2021): $2.6M led by The Chartered Group
Series A (2025): $6.6M supported by Japan Israel High Tech Ventures 2 LP
Key Investors in Pepticom
The Chartered Group
The Chartered Group is an investor with a broad focus, likely providing strategic capital for companies aiming for significant market impact.
Japan Israel High Tech Ventures 2 LP
Japan Israel High Tech Ventures 2 LP is a venture capital fund that typically invests in technology and innovation, potentially focusing on cross-border collaborations.
Chartered Group
Chartered Group appears to be a repeat investor, indicating confidence in Pepticom's long-term vision and execution capabilities.
What's next for Pepticom?
The substantial enterprise-level funding positions Pepticom for accelerated growth and market penetration. This capital infusion is expected to fuel further research and development, expand their AI-driven platform capabilities, and potentially broaden their pipeline of peptide drug candidates. The strategic investment suggests a focus on scaling operations and solidifying market presence in the competitive biopharmaceutical landscape. Pepticom's trajectory indicates a strong emphasis on advancing 21st-century medicine through enhanced drug discovery and development.
See full Pepticom company page
